Dr Martens PLC (LSE:DOCS) said trading so far this year has been in line with expectations with the bootmaker reiterating its full-year guidance.
Alongside its strong results for fiscal 2022, published on 1 June, the company forecast high-teens revenue growth for the year to March 2023. The upgrade resulted from price increases planned for this year's autumn/winter season (AW22) and spring/summer (SS23).
In a statement issued ahead of today's AGM, Dr Martens said it implemented the AW22 price increases fully from early July.
In the first three months of this year, ecommerce was in line with fourth-quarter 2022 and retail continued its "strong recovery", the company said, adding that it has opened 10 new stores to date.
"The early months of our financial year are typically the smallest period of the year, representing the tail end of the spring/summer trading period," it noted.
The wholesale order book continued to increase beyond 85% of the full-year level as disclosed in the results for FY2022.
"All our third-party factories are open and operating at 90-95% planned capacity, and shipping lead times continue to improve steadily," the company said.